{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:35:11Z","timestamp":1780497311854,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00408-024-00781-4","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:42:51Z","timestamp":1736167371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Respiratory Outcomes and Aspergillus Serology Following Elexacaftor\/Tezacaftor\/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection"],"prefix":"10.1007","volume":"203","author":[{"given":"Chiara","family":"Lanfranchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Silvia","family":"Orena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Rizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"781_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"J Elborn","year":"2016","unstructured":"Elborn J (2016) Cystic fibrosis. Lancet 388:2519\u20132531. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","journal-title":"Lancet"},{"key":"781_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/S11046-017-0184-Y","volume":"183","author":"A Singh","year":"2018","unstructured":"Singh A, Ralhan A, Schwarz C et al (2018) Fungal pathogens in CF airways: leave or treat? Mycopathologia 183:119\u2013137. https:\/\/doi.org\/10.1007\/S11046-017-0184-Y","journal-title":"Mycopathologia"},{"issue":"8","key":"781_CR3","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/microorganisms11082013","volume":"11","author":"TS Poore","year":"2023","unstructured":"Poore TS, Zemanick ET (2023) Infection, Allergy, and Inflammation: the role of Aspergillus fumigatus in cystic fibrosis. Microorganisms 11(8):2013. https:\/\/doi.org\/10.3390\/microorganisms11082013","journal-title":"Microorganisms"},{"key":"781_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1164\/RCCM.201106-1027OC","volume":"185","author":"N Chaudhary","year":"2012","unstructured":"Chaudhary N, Datta K, Askin FB et al (2012) Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med 185:301\u2013310. https:\/\/doi.org\/10.1164\/RCCM.201106-1027OC","journal-title":"Am J Respir Crit Care Med"},{"key":"781_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/ADC.65.5.507","volume":"65","author":"EJ Simmonds","year":"1990","unstructured":"Simmonds EJ, Littlewood JM, Evans EGV (1990) Cystic fibrosis and allergic bronchopulmonary aspergillosis. Arch Dis Child 65:507\u2013511. https:\/\/doi.org\/10.1136\/ADC.65.5.507","journal-title":"Arch Dis Child"},{"key":"781_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/J.JCF.2024.01.005","volume":"23","author":"PR Burgel","year":"2024","unstructured":"Burgel PR, Southern KW, Addy C et al (2024) Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros 23:187\u2013202. https:\/\/doi.org\/10.1016\/J.JCF.2024.01.005","journal-title":"J Cyst Fibros"},{"key":"781_CR7","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet (London, England) 394:1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet (London, England)"},{"key":"781_CR8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMOA1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P et al (2019) Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a Single Phe508del allele. N Engl J Med 381:1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMOA1908639","journal-title":"N Engl J Med"},{"issue":"6","key":"781_CR9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","volume":"23","author":"G Alicandro","year":"2024","unstructured":"Alicandro G, Gramegna A, Bellino F et al (2024) Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis. J Cyst Fibros 23(6):1072\u20131079. https:\/\/doi.org\/10.1016\/j.jcf.2024.04.013","journal-title":"J Cyst Fibros"},{"key":"781_CR10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1164\/RCCM.201908-1585OC","volume":"201","author":"O Breuer","year":"2020","unstructured":"Breuer O, Schultz A, Garratt LW et al (2020) Aspergillus infections and progression of structural lung disease in children with cystic fibrosis. Am J Respir Crit Care Med 201:688\u2013696. https:\/\/doi.org\/10.1164\/RCCM.201908-1585OC","journal-title":"Am J Respir Crit Care Med"},{"key":"781_CR11","doi-asserted-by":"publisher","DOI":"10.1086\/376525","author":"DA Stevens","year":"2003","unstructured":"Stevens DA, Moss RB, Kurup VP et al (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis\u2014state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis. https:\/\/doi.org\/10.1086\/376525","journal-title":"Clin Infect Dis"},{"key":"781_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1055\/s-0042-1759882","volume":"44","author":"C Schwarz","year":"2023","unstructured":"Schwarz C (2023) Clinical relevance of fungi in cystic fibrosis. Semin Respir Crit Care Med 44:252\u2013259. https:\/\/doi.org\/10.1055\/s-0042-1759882","journal-title":"Semin Respir Crit Care Med"},{"key":"781_CR13","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Barjaktarevic IZ et al (2019) Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 200:E70\u2013E88. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST","journal-title":"Am J Respir Crit Care Med"},{"key":"781_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ et al (2012) Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324\u20131343. https:\/\/doi.org\/10.1183\/09031936.00080312","journal-title":"Eur Respir J"},{"key":"781_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1128\/AAC.05077-11","volume":"56","author":"PR Burgel","year":"2012","unstructured":"Burgel PR, Baixench MT, Amsellem M et al (2012) High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 56:869\u2013874. https:\/\/doi.org\/10.1128\/AAC.05077-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"781_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/J.JACI.2013.04.007","volume":"132","author":"CG Baxter","year":"2013","unstructured":"Baxter CG, Dunn G, Jones AM et al (2013) Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 132(3):560-566.e10. https:\/\/doi.org\/10.1016\/J.JACI.2013.04.007","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"781_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/FCIMB.2020.00372","volume":"24","author":"AJ Currie","year":"2020","unstructured":"Currie AJ, Main ET, Wilson HM et al (2020) CFTR Modulators dampen Aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes. Front Cell Infect Microbiol 24(10):372. https:\/\/doi.org\/10.3389\/FCIMB.2020.00372","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"781_CR18","doi-asserted-by":"publisher","first-page":"e0151623","DOI":"10.1128\/MBIO.01516-23","volume":"14","author":"JT Jones","year":"2023","unstructured":"Jones JT, Morelli KA, Vesely EM et al (2023) The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms. MBio 14(5):e0151623. https:\/\/doi.org\/10.1128\/MBIO.01516-23","journal-title":"MBio"},{"key":"781_CR19","unstructured":"Zolin A, Adamoli A, Bakkeheim E van RJ et al (2024) ECFSPR annual report 2022. www.ecfs.eu\/ecfspr. Accessed 24 Jul 2024"},{"key":"781_CR20","unstructured":"European Cystic Fibrosis Society (2020) ECFSPR annual report 2018. www.ecfs.eu\/ecfspr. Accessed 24 Jul 2024"},{"key":"781_CR21","doi-asserted-by":"publisher","unstructured":"Campagna G, Amato A, Majo F et al (2024) [Italian Cystic Fibrosis Registry (ICFR). Report 2021\u20132022]. Epidemiologia e prevenzione 48:1\u201341. https:\/\/doi.org\/10.19191\/EP24.2.S2.031","DOI":"10.19191\/EP24.2.S2.031"},{"key":"781_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1513\/ANNALSATS.201902-122OC","volume":"16","author":"FJ Frost","year":"2019","unstructured":"Frost FJ, Nazareth DS, Charman SC et al (2019) Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data. Ann Am Thorac Soc 16:1375\u20131382. https:\/\/doi.org\/10.1513\/ANNALSATS.201902-122OC","journal-title":"Ann Am Thorac Soc"},{"key":"781_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/THORAXJNL-2017-210394","volume":"73","author":"L Bessonova","year":"2018","unstructured":"Bessonova L, Volkova N, Higgins M et al (2018) Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax 73:731\u2013740. https:\/\/doi.org\/10.1136\/THORAXJNL-2017-210394","journal-title":"Thorax"},{"key":"781_CR24","doi-asserted-by":"publisher","first-page":"175346662412540","DOI":"10.1177\/17534666241254090","volume":"18","author":"M Al Shakirchi","year":"2024","unstructured":"Al Shakirchi M, Sorjonen K, Hjelte L et al (2024) Impact of lumacaftor\/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden. Ther Adv Respir Dis 18:17534666241254090. https:\/\/doi.org\/10.1177\/17534666241254090","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"781_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/SPECTRUM.02251-22","volume":"11","author":"R Enaud","year":"2023","unstructured":"Enaud R, Lussac-Sorton F, Charpentier E et al (2023) Effects of lumacaftor\u2013ivacaftor on airway microbiota-mycobiota and inflammation in patients with cystic fibrosis appear to be linked to pseudomonas aeruginosa chronic colonization. Microbiol Spectr 11(2):e0225122. https:\/\/doi.org\/10.1128\/SPECTRUM.02251-22","journal-title":"Microbiol Spectr"},{"issue":"1","key":"781_CR26","doi-asserted-by":"publisher","first-page":"18999","DOI":"10.1038\/S41598-020-75886-W","volume":"10","author":"U D\u00fcesberg","year":"2020","unstructured":"D\u00fcesberg U, Wosniok J, Naehrlich L et al (2020) Risk factors for respiratory Aspergillus fumigatus in German cystic fibrosis patients and impact on lung function. Sci Rep 10(1):18999. https:\/\/doi.org\/10.1038\/S41598-020-75886-W","journal-title":"Sci Rep"},{"key":"781_CR27","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/J.JCF.2022.09.007","volume":"21","author":"A Chesnay","year":"2022","unstructured":"Chesnay A, Bailly \u00c9, Cosson L et al (2022) Advent of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights. J Cyst Fibros 21:1084\u20131085. https:\/\/doi.org\/10.1016\/J.JCF.2022.09.007","journal-title":"J Cyst Fibros"},{"issue":"6","key":"781_CR28","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/J.IJID.2009.06.028","volume":"14","author":"A Carvalho","year":"2010","unstructured":"Carvalho A, Cunha C, Pasqualotto AC et al (2010) Genetic variability of innate immunity impacts human susceptibility to fungal diseases. Int J Infect Dis 14(6):e460\u2013e468. https:\/\/doi.org\/10.1016\/J.IJID.2009.06.028","journal-title":"Int J Infect Dis"},{"key":"781_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1067\/MAI.2000.109913","volume":"106","author":"B Chauhan","year":"2000","unstructured":"Chauhan B, Santiago L, Hutcheson PS et al (2000) Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 106:723\u2013729. https:\/\/doi.org\/10.1067\/MAI.2000.109913","journal-title":"J Allergy Clin Immunol"},{"key":"781_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/S13223-016-0152-Y","volume":"12","author":"NLD Overton","year":"2016","unstructured":"Overton NLD, Denning DW, Bowyer P, Simpson A (2016) Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. Allergy Asthma Clin Immunol 12:47. https:\/\/doi.org\/10.1186\/S13223-016-0152-Y","journal-title":"Allergy Asthma Clin Immunol"},{"key":"781_CR31","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11046-021-00541-5","volume":"186","author":"A Bercusson","year":"2021","unstructured":"Bercusson A, Jarvis G, Shah A (2021) CF Fungal disease in the age of CFTR modulators. Mycopathologia 186:655\u2013664. https:\/\/doi.org\/10.1007\/s11046-021-00541-5","journal-title":"Mycopathologia"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00781-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-024-00781-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00781-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:42:11Z","timestamp":1766378531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-024-00781-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s00408-024-00781-4","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Gramegna, Francesco Blasi, and Valeria Dacc\u00f2 report honoraria for lectures and consultancy fees from Vertex Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"24"}}